716-1167

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2012-10-08

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Moderate BLISTER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-03 (study day 57.0); relationship: POSSIBLE

mild assessed

Mild HYPERSENSITIVITY — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-10 (study day 154.0); relationship: NONE

mild assessed

Mild HYPERSENSITIVITY — outcome: RECOVERED/RESOLVED; onset 2013-03-10 (study day 154.0); relationship: NONE

moderate assessed

Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-11-17 (study day 41.0); relationship: NONE

moderate assessed

Moderate SWELLING — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-11-17 (study day 41.0); relationship: NONE

Data queries

No data queries.